CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FDG PET/CT 监测下的神经淋巴瘤病 CAR-T 细胞治疗
英文原题：Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT.
查看英文原题
Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
18 F-FDG PET/CT用于评估一名34岁男性可能的复发性B细胞淋巴母细胞淋巴瘤。图像显示神经根和周围神经有多处活性增高的病灶。活检证实了神经淋巴瘤病的诊断。接受化疗后，PET/CT显示疾病进展。该患者随后接受了CD-19CAR-T 细胞治疗。CAR-T 细胞治疗后30天进行的随访PET/CT显示无异常FDG活性。
展开英文摘要原文
18 F-FDG PET/CT was performed to evaluate possible recurrent B-cell lymphoblastic lymphoma in a 34-year-old man. The images showed multiple foci of increased activity in the nerve root and peripheral nerve. A biopsy confirmed the diagnosis of neurolymphomatosis. After receiving chemotherapy, PET/CT showed progressive disease. The patient subsequently received the CD-19 chimeric antigen receptor T-cell therapy. A follow-up PET/CT acquired 30 days after chimeric antigen receptor T-cell therapy revealed no abnormal FDG activity.
论文信息
- 作者
- Li S、Wang H、Wang G、Lu X、Yang J
- 单位
- From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China.China
- 文献类型
- 病例报告
- 期刊
- Clinical nuclear medicine2023 May 1
- 原文标识
- PubMed 36716490 · DOI 10.1097/RLU.0000000000004584